Autoplex Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to high prevalence of hemophilia inhibitors, limited effectiveness of standard factor therapy, hospital reliance on bypassing agents, established plasma derived products, specialist hematology adoption.

The growth in the forecast period can be attributed to growth in diagnosed inhibitor patients, expansion of specialty bleeding centers, rising awareness of rapid bleed control, improved access to specialty pharmacies, supportive reimbursement policies. Major trends in the forecast period include continued use of bypassing agents in hemophilia, rising demand for inhibitor management therapies, increased hospital based bleeding control, focus on rapid hemostasis products, growth in rare bleeding disorder treatments.

The increasing prevalence of hemophilia is expected to drive the growth of the autoplex market. Hemophilia is a rare genetic bleeding disorder in which the blood does not clot properly due to a deficiency or dysfunction of specific clotting factors. Its rising prevalence is attributed to genetic inheritance and improved diagnostic capabilities. Autoplex supports hemophilia management by providing targeted clotting factor replacement therapy, helping patients with varying severity levels maintain effective clotting, reduce bleeding episodes, and improve overall quality of life. For example, in July 2025, according to the National Blood Authority, an Australia-based blood management agency, 2,788 patients were living with hereditary haemophilia A (HMA) in 2023-2024, up from 2,681 in 2022-2023. Therefore, the growing prevalence of hemophilia is fueling the autoplex market.

The rise in the number of surgical procedures is expected to further boost the autoplex market. Surgical procedures involve medical interventions using instruments to treat or manage diseases, injuries, or conditions through invasive or minimally invasive techniques. The increase in surgeries is driven by factors such as aging populations, medical technology advancements, higher prevalence of chronic diseases, and improved healthcare access. Autoplex is used during surgeries to enhance hemostasis by delivering clotting factors directly at bleeding sites, promoting faster and more effective clot formation. For instance, in June 2024, according to the American Society of Plastic Surgeons (ASPS), liposuction was the most popular procedure in 2023, with nearly 350,000 performed - a 7% increase from 2022 - while hand surgeries totaled 207,887 (up 2%) and maxillofacial surgeries reached 52,868 (up 1%). Therefore, the increasing number of surgical procedures is driving the autoplex market.

Rising healthcare expenditure is also expected to propel the autoplex market. Healthcare expenditure encompasses the financial resources spent on medical treatments, infrastructure, and healthcare programs. Growth in healthcare spending is influenced by factors such as an aging population, chronic disease prevalence, medical technology advancements, inflation, and higher demand for quality care. Adequate healthcare infrastructure ensures effective use of Autoplex by providing necessary facilities, trained personnel, and technological support for optimal patient care. For example, in May 2024, according to the Office for National Statistics, a UK-based government agency, total healthcare expenditure increased by 5.6% in nominal terms from 2022 to 2023, compared with 0.9% growth in 2022. Therefore, rising healthcare expenditure is driving the growth of the autoplex market.

Major companies operating in the autoplex market are Baxter International Inc.

North America was the largest region in the autoplex market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the autoplex market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the autoplex market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the autoplex market by increasing costs for plasma derived raw materials, fractionation equipment, and sterile packaging supplies. These impacts are more pronounced in regions reliant on imported plasma products, including asia pacific and latin america. Hospital procurement budgets have experienced pricing pressure. However, tariffs have promoted domestic plasma processing investments. This enhances long term availability of coagulation therapies.

The autoplex market research report is one of a series of new reports that provides autoplex market statistics, including autoplex industry global market size, regional shares, competitors with a autoplex market share, detailed autoplex market segments, market trends and opportunities, and any further data you may need to thrive in the autoplex industry. This autoplex market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Autoplex is a coagulation factor therapy used to manage bleeding episodes in individuals with hemophilia who have developed inhibitors against Factor VIII or IX. It is specifically designed to control and prevent bleeding by supporting clotting mechanisms in these patients.

The primary indications for autoplex include hemophilia, thrombotic thrombocytopenic purpura (TTP), autoimmune disorders, and other immunological conditions. Hemophilia is a genetic bleeding disorder in which the blood does not clot properly due to a deficiency or dysfunction of clotting factors. The therapy is used by both adult and pediatric populations and is distributed through multiple channels, including hospital pharmacies, specialty pharmacies, and direct-to-consumer platforms.

The autoplex market consists of sales of the autoPlex M4 mixer and delivery system, delivery injector, and VertePort cement cannula. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.